Mourad N, Nenquin M, Henquin J. cAMP-mediated and metabolic amplification of insulin secretion are distinct pathways sharing independence of β-cell microfilaments. Endocrinology. 2012;153:4644-54 pubmed

Vendrell J, El Bekay R, Peral B, Garcia Fuentes E, Megia A, Macias Gonzalez M, et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology. 2011;152:4072-9 pubmed publisher

Gao H, Niu G, Yang M, Quan Q, Ma Y, Murage E, et al. PET of insulinoma using ¹?F-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm. 2011;8:1775-82 pubmed publisher

Liu S, Chen P, Xu J. [Effects of GLP-1(7-36)NH2 on insulin secretion and the changes of intracellular cAMP and insulin mRNA expression]. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2004;20:217-8 pubmed

Neary N, Small C, Druce M, Park A, Ellis S, Semjonous N, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology. 2005;146:5120-7 pubmed

Lee S, Lee S, Youn Y, Na D, Chae S, Byun Y, et al. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem. 2005;16:377-82 pubmed

Ozyazgan S, Kutluata N, Afşar S, Ozdas S, Akkan A. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology. 2005;74:119-26 pubmed

Claret M, Corominola H, Canals I, Nadal B, Chavanieu A, Pfeiffer B, et al. S 23521 decreases food intake and body weight gain in diet-induced obese rats. Obes Res. 2004;12:1596-603 pubmed

Wolf R, Hoffmann T, Rosche F, Demuth H. Simultaneous determination of incretin hormones and their truncated forms from human plasma by immunoprecipitation and liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;803:91-9 pubmed

Green B, Mooney M, Gault V, Irwin N, Bailey C, Harriott P, et al. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39). Metabolism. 2004;53:252-9 pubmed

Schick R, Zimmermann J, vorm Walde T, Schusdziarra V. Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1427-35 pubmed

Vella A, Shah P, Reed A, Adkins A, Basu R, Rizza R. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia. 2002;45:1410-5 pubmed

Mooney M, Abdel Wahab Y, McKillop A, O Harte F, Flatt P. Evaluation of glycated glucagon-like peptide-1(7-36)amide in intestinal tissue of normal and diabetic animal models. Biochim Biophys Acta. 2002;1569:75-80 pubmed

Creutzfeldt W. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents. Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S288-303 pubmed

Ding W, Kitasato H, Matsuura H. Involvement of calmodulin in glucagon-like peptide 1(7-36) amide-induced inhibition of the ATP-sensitive K+ channel in mouse pancreatic beta-cells. Exp Physiol. 2001;86:331-9 pubmed

Bertin E, Arner P, Bolinder J, Hagström Toft E. Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J Clin Endocrinol Metab. 2001;86:1229-34 pubmed

Rosche F, Schmidt J, Hoffmann T, Pauly R, McIntosh C, Pederson R, et al. Kinetic analysis of enzymatic and nonenzymatic degradation of peptides by MALDI-TOFMS. Methods Mol Biol. 2000;146:251-72 pubmed

Ranganath L, Morgan L. An osmotic stimulus-mediating glucagon-like peptide-1 (7-36 amide) (GLP-1) secretion in acarbose-induced sucrose malabsorption?. Nutrition. 2000;16:64-5 pubmed

Iritani N, Sugimoto T, Fukuda H, Komiya M, Ikeda H. Oral triacylglycerols regulate plasma glucagon-like peptide-1(7-36) and insulin levels in normal and especially in obese rats. J Nutr. 1999;129:46-50 pubmed

Zueco J, Esquifino A, Chowen J, Alvarez E, Castrillon P, Blazquez E. Coexpression of glucagon-like peptide-1 (GLP-1) receptor, vasopressin, and oxytocin mRNAs in neurons of the rat hypothalamic supraoptic and paraventricular nuclei: effect of GLP-1(7-36)amide on vasopressin and oxytocin release. J Neurochem. 1999;72:10-6 pubmed

Furuse M, Bungo T, Shimojo M, Masuda Y, Saito N, Hasegawa S, et al. Effects of various N-terminal fragments of glucagon-like peptide-1(7-36) on food intake in the neonatal chick. Brain Res. 1998;807:214-7 pubmed

Asarian L, Corp E, Hrupka B, Geary N. Intracerebroventricular glucagon-like peptide-1 (7-36) amide inhibits sham feeding in rats without eliciting satiety. Physiol Behav. 1998;64:367-72 pubmed

Faulkner A, Martin P. Changes in the concentrations of glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide during the lactation cycle in goats. J Dairy Res. 1998;65:433-41 pubmed

Pohl M, Wank S. Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian ho. J Biol Chem. 1998;273:9778-84 pubmed

Gama R, Norris F, Morgan L, Hampton S, Wright J, Marks V. Elevated post-prandial gastric inhibitory polypeptide concentrations in hypertriglyceridaemic subjects. Clin Sci (Lond). 1997;93:343-7 pubmed

Suga S, Kanno T, Nakano K, Takeo T, Dobashi Y, Wakui M. GLP-I(7-36) amide augments Ba2+ current through L-type Ca2+ channel of rat pancreatic beta-cell in a cAMP-dependent manner. Diabetes. 1997;46:1755-60 pubmed

Gutniak M, Orskov C, Holst J, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992;326:1316-22 pubmed